Form 4: GRI Bio Director Szekeres Granted Stock Options

GRI Bio, Inc. Director David Leslie Szekeres was granted 39,897 stock options with an exercise price of $1.93, vesting over one year.

Summary

• David Leslie Szekeres, a Director of GRI Bio, Inc. (GRI), reported the acquisition of stock options.
• The transaction occurred on September 18, 2025.
• Szekeres was granted 39,897 stock options.
• The exercise price for these options is $1.93 per share.
• The options have an expiration date of September 18, 2035.
• Of the total options, 29,293 shares vested immediately on the grant date.
• The remaining 9,974 shares will vest in four substantially equal quarterly installments, becoming fully vested on the first anniversary of the grant date (September 18, 2026).
• Following this transaction, Szekeres directly beneficially owns 39,897 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a positive signal as it aligns the director's interests with shareholders. However, it is a routine compensation event and does not indicate significant operational or financial news.

Positives

• The grant of stock options to a director aligns management's interests with shareholders, incentivizing long-term performance.
• The options have a 10-year expiration, providing a long-term incentive for the director.

Risks

• If the company's stock price does not exceed the exercise price of $1.93 per share, the granted options may expire worthless.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction.

Industry Context

Granting stock options to directors is a common practice across various industries, including biotechnology, to attract and retain talent, and to align the interests of directors with those of shareholders by providing an equity stake in the company's future success.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice within the industry.
• The vesting structure, which includes immediate vesting for a portion and time-based vesting for the remainder, is typical for incentivizing both immediate commitment and sustained performance.

Related Party Transactions

• The grant of stock options to David Leslie Szekeres, a Director of GRI Bio, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term performance. Future exercise of options could lead to minor dilution.
• Management: The director's compensation package is enhanced, providing an incentive for continued service and performance.

Next Steps

• The remaining 9,974 stock options will vest in four substantially equal quarterly installments, with full vesting by September 18, 2026.
• The director may choose to exercise the vested options at any time before the expiration date of September 18, 2035, provided the stock price is above the exercise price.

Key Dates

Keywords

GRI Bio Inc., GRI, stock options, insider transaction, Form 4, director compensation, equity grant, David Leslie Szekeres, beneficial ownership